PubRank

Nikolaus Schultz

Author PubWeight™ 154.87‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012 26.98
2 Integrative genomic profiling of human prostate cancer. Cancer Cell 2010 23.61
3 Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013 19.54
4 Integrated genomic characterization of endometrial carcinoma. Nature 2013 14.29
5 Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res 2010 9.18
6 Mutual exclusivity analysis identifies oncogenic network modules. Genome Res 2011 7.22
7 Emerging landscape of oncogenic signatures across human cancers. Nat Genet 2013 6.48
8 Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 2015 5.71
9 Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 2013 4.35
10 Automated network analysis identifies core pathways in glioblastoma. PLoS One 2010 3.64
11 A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A 2012 2.85
12 Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 2009 2.51
13 Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res 2013 2.26
14 The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A 2009 2.09
15 Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 2013 1.92
16 Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. Cancer Discov 2011 1.85
17 The mutational landscape of adenoid cystic carcinoma. Nat Genet 2013 1.83
18 Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One 2012 1.76
19 Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell 2011 1.74
20 Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res 2012 1.71
21 Pattern discovery and cancer gene identification in integrated cancer genomic data. Proc Natl Acad Sci U S A 2013 1.60
22 Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res 2014 1.57
23 Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res 2014 1.55
24 Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov 2012 1.50
25 An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst 2013 1.42
26 Analysis of microRNA-target interactions across diverse cancer types. Nat Struct Mol Biol 2013 1.41
27 Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 2016 1.36
28 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res 2011 1.36
29 Integrative subtype discovery in glioblastoma using iCluster. PLoS One 2012 1.29
30 Defining the spermatogonial stem cell. Dev Biol 2004 1.23
31 MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. J Pathol 2013 1.17
32 Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles. PLoS One 2011 1.09
33 The molecular diversity of Luminal A breast tumors. Breast Cancer Res Treat 2013 1.07
34 Cancer cells preferentially lose small chromosomes. Int J Cancer 2012 1.02
35 Comprehensive analysis of long non-coding RNAs in ovarian cancer reveals global patterns and targeted DNA amplification. PLoS One 2013 0.99
36 Integrating biological pathways and genomic profiles with ChiBE 2. BMC Genomics 2014 0.94
37 BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Am J Surg Pathol 2013 0.92
38 MEF promotes stemness in the pathogenesis of gliomas. Cell Stem Cell 2012 0.92
39 Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol 2012 0.87
40 Expression patterns of mitotic and meiotic cell cycle regulators in testicular cancer and development. Int J Cancer 2005 0.85
41 Using MEMo to discover mutual exclusivity modules in cancer. Curr Protoc Bioinformatics 2013 0.84
42 53BP1 is a haploinsufficient tumor suppressor and protects cells from radiation response in glioma. Cancer Res 2012 0.82
43 Integrative genome-wide analysis of the determinants of RNA splicing in kidney renal clear cell carcinoma. Pac Symp Biocomput 2015 0.75
44 Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017 0.75
45 Erratum: The metabolic co-regulator PGC1α suppresses prostate cancer metastasis. Nat Cell Biol 2017 0.75
46 Integrative Clinical Genomics of Advanced Prostate Cancer. Cell 2015 0.75